EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis, and evaluation of new benzimidazole‏ ‏‎thiourea ‎derivatives as antitumor agents

Mohamed H Aboutaleb, Nadia S El-Gohary, Hazem A Ghabbour, Mohamed M El-Kerdawy

Archiv der Pharmazie · 2023

DOI: 10.1002/ardp.202300269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2023. Verfasst von Mohamed H Aboutaleb und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel benzimidazole thiourea derivatives were designed and synthesized based on sorafenib as a lead compound. The benzimidazole moiety was traded by the pyridine ring to enhance the hydrophobic interaction and retain hydrogen bonding in the hinge region, while lipophilic moieties with different bulkiness were employed in the deep hydrophobic pocket for better hydrophobic interactions. Thiourea as a urea bioisostere was also utilized. Substantial activity was demonstrated against a leukemia subpanel in an in vitro antitumor screening at the NCI. In the single‐dose assay, compounds 7i , 7j , and 7l had a GI%) higher than sorafenib against most leukemia cell lines (GI% = 86.2%–137.1%), while in the five‐dose assay, compound 7l outperformed sorafenib against the HL‐60(TB) and SR leukemia cell lines in terms of GI 50 , TGI, and LC 50 . Compound 7l also caused cycle arrest at the G0–G1 and S phases in the HL‐60(TB) leukemia cell line and induced apoptosis via elevating the Bax/Bcl‐2 ratio and increasing caspases 3, 7, and 9 by 5.1‐, 3.2‐, and 5.2‐fold, respectively. Compounds 7i , 7j , and 7l also inhibited the vascular ‎endothelial growth factor receptor‐2 (VEGFR‐2), B‐Raf (V600E) , and platelet‐derived growth factor receptor ‎beta (PDGFR‐β) enzymes with an IC 50 range of 0.063–0.44 μM. COMPARE analysis and a molecular docking study were also performed to predict the possible mechanism of action and binding mode, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLeukemiaHumansSorafenibStructure-Activity RelationshipMolecular Docking SimulationVascular Endothelial Growth Factor AProtein Kinase InhibitorsDrug Screening Assays, AntitumorVascular Endothelial Growth Factor Receptor-2ThioureaBenzimidazolesCell ProliferationMolecular StructureDrug Design

Stichwörter der Autor:innen

antitumorapoptosis induction‎benzimidazolesmolecular dockingmultikinase inhibitors

Substanzen

SorafenibVascular Endothelial Growth Factor AProtein Kinase InhibitorsAntineoplastic AgentsVascular Endothelial Growth Factor Receptor-2ThioureaBenzimidazoles

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University, New Damietta, Egypt.

Förderung

  • None

Zitieren

APA

Aboutaleb, M. H., El-Gohary, N. S., Ghabbour, H. A., & El-Kerdawy, M. M. (2023). Design, synthesis, and evaluation of new benzimidazole‏ ‏‎thiourea ‎derivatives as antitumor agents. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300269

Vancouver

Aboutaleb MH, El-Gohary NS, Ghabbour HA, El-Kerdawy MM. Design, synthesis, and evaluation of new benzimidazole‏ ‏‎thiourea ‎derivatives as antitumor agents. Archiv der Pharmazie. 2023. doi:10.1002/ardp.202300269

BibTeX
@article{Aboutaleb2023,
  author = {Aboutaleb, Mohamed H and El-Gohary, Nadia S and Ghabbour, Hazem A and El-Kerdawy, Mohamed M},
  title = {Design, synthesis, and evaluation of new benzimidazole‏ ‏‎thiourea ‎derivatives as antitumor agents},
  journal = {Archiv der Pharmazie},
  year = {2023},
  doi = {10.1002/ardp.202300269}
}
Kostenlos starten →